Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and neuropathologies in rats

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 1029-1039

  Xia, Yiyuan ^a   Liu, Rong ^a   Chen, Rong ^a   Tian, Qing ^a   Zeng, Kuan ^a   Hu, Jichang ^a   Liu, Xinghua ^a   Wang, Qun ^a   Wang, Peng ^b,c   Wang, Xiao Chuan ^a   Wang, Jian Zhi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Jiangsu Aosaikang Pharmaceutical Co Ltd   (China)

^c Jiangsu Simcere Pharmaceutical RandD Co Ltd   (China)

Author keywords

Alzheimer's disease; GSK 3 ; hyperhomocysteinemia; PP2A; SCR1693; tau

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GLYCOGEN SYNTHASE KINASE 3BETA; NILVADIPINE; PHOSPHOPROTEIN PHOSPHATASE 2A; POSTSYNAPTIC DENSITY PROTEIN 95; SCR 1693; SYNAPSIN I; TAU PROTEIN; UNCLASSIFIED DRUG; HOMOCYSTEINE; INDAN DERIVATIVE; NERVE PROTEIN; NIFEDIPINE; PIPERIDINE DERIVATIVE; SCR1693; TACRINE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CELL STRUCTURE; CONTROLLED STUDY; DENDRITE; DRUG EFFECT; ENZYME ACTIVITY; HYPERHOMOCYSTEINEMIA; MALE; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE; SPINE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN DISEASES; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; HIPPOCAMPUS; MAZE TEST; MEMORY DISORDERS; METABOLISM; PATHOLOGY; PREFRONTAL CORTEX; SILVER STAINING; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; BRAIN DISEASES; CALCIUM CHANNEL BLOCKERS; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HIPPOCAMPUS; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; INDANS; MALE; MAZE LEARNING; MEMORY DISORDERS; NERVE TISSUE PROTEINS; NIFEDIPINE; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SILVER STAINING; TACRINE;

EID: 84907144777     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140597     Document Type: Article

References (49)

1. Braak H, Braak E, Grundke-Iqbal I, Iqbal K (1986) Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett 65, 351-355.
2. Wang JZ, Grundke-Iqbal I, Iqbal K (1996) Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A,-2B and-1. Brain Res Mol Brain Res 38, 200-208.
3. Wang JZ, Wu Q, Smith A, Grundke-Iqbal I, Iqbal K (1998) Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett 436, 28-34.
4. Iqbal K, Grundke-Iqbal I (2008) Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12, 38-55.
5. Talesa VN (2001) Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 122, 1961-1969.
6. Black SE, Doody R, Li H, McRae T, Jambor KM,XuY, SunY, Perdomo CA, Richardson S (2007) Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69, 459-469.
7. Feldman H, Gauthier S, Hecker J,Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Investigators Group (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57, 613-620.
8. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group (2005) Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 20, 559-569.
9. Luger P, Weber M, Dittrich B (2012) Electron density study of the anti-Alzheimer's disease drug donepezil from conventional X-ray data and invariom database application. Future Med Chem 4, 1399-1407.
10. Veloso AJ, Chow AM, Dhar D, Tang DW, Ganesh HV, Mikhaylichenko S, Brown IR, Kerman K (2013) Biological activity of sym-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer's disease. ACS Chem Neurosci 4, 924-929.
11. Wang Y, Tang XC, Zhang HY (2012) Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice. J Neurosci Res 90, 508-517.
12. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A, Severe Alzheimer's Disease Study G (2006) Donepezil in patients with severe Alzheimer's disease: Doubleblind, parallel-group, placebo-controlled study. Lancet 367, 1057-1065.
13. Kruman I, Guo Q, Mattson MP (1998) Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J Neurosci Res 51, 293-308.
14. Mattson MP, Rydel RE (1992) beta-Amyloid precursor protein and Alzheimer's disease: The peptide plot thickens. Neurobiol Aging 13, 617-621.
15. Selkoe DJ (1989) Biochemistry of altered brain proteins in Alzheimer's disease. Annu Rev Neurosci 12, 463-490.
16. Feng Y, Xia Y, Yu G, Shu X, Ge H, Zeng K, Wang J, Wang X (2013) Cleavage of GSK-3beta by calpain counteracts the inhibitory effect of Ser9 phosphorylation on GSK-3beta activity induced by H(2)O(2). J Neurochem 126, 234-242.
17. Chen CS, Yeh YC, Chang YS, Huang MF (2011) Plasma homocysteine level and apathy in Alzheimer's disease. J Am Geriatr Soc 59, 1752-1754.
18. Rajagopalan P, Hua X, Toga AW, Jack CR Jr, Weiner MW, ThompsonPM(2011)Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport 22, 391-395.
19. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483.
20. Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, Refolo L, Petanceska S, Pappolla MA (2006) Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 22, 651-656.
21. Zhang CE, Tian Q,WeiW, Peng JH, Liu GP, ZhouXW,Wang Q, Wang DW, Wang JZ (2008) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 29, 1654-1665.
22. Zhang CE, Wei W, Liu YH, Peng JH, Tian Q, Liu GP, Zhang Y, Wang JZ (2009) Hyperhomocysteinemia increases betaamyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 174, 1481-1491.
23. Poddar R, Paul S (2013)Novel crosstalk betweenERKMAPK and p38 MAPK leads to homocysteine-NMDA receptormediated neuronal cell death. J Neurochem 124, 558-570.
24. Ho PI, Ortiz D, Rogers E, Shea TB (2002) Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70, 694-702.
25. Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Pratico D (2010) Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res 7, 140-149.
26. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11, 47-60.
27. Roberts TF, Tschida KA, Klein ME,Mooney R (2010) Rapid spine stabilization and synaptic enhancement at the onset of behavioural learning. Nature 463, 948-952.
28. Hofer SB, Mrsic-Flogel TD, Bonhoeffer T, HubenerM(2009) Experience leaves a lasting structural trace in cortical circuits. Nature 457, 313-317.
29. Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, Grundke-Iqbal I, Iqbal K (2010) The carboxyterminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J 24, 4420-4432.
30. Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25, 59-68.
31. Chai GS, Jiang X, Ni ZF, Ma ZW, Xie AJ, Cheng XS, Wang Q, Wang JZ, Liu GP (2013) Betaine attenuates Alzheimerlike pathological changes and memory deficits induced by homocysteine. J Neurochem 124, 388-396.
32. Singh TJ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Modulation of GSK-3-catalyzed phosphorylation of microtubuleassociated protein tau by non-proline-dependent protein kinases. FEBS Lett 358, 4-8.
33. Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D'Anselmi F, Coluccia P, Calamandrei G, Scarpa S (2008) Bvitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain Sadenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 37, 731-746.
34. Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, Makela M, Oinas M, Paetau A, Scheltens P, van Straaten EC, Sulkava R, Solomon A (2013) Plasma homocysteine, Alzheimer and cerebrovascular pathology: A population-based autopsy study. Brain 136, 2707-2716.
35. Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 27, 2751-2759.
36. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 66, 137-147.
37. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16, 881-891.
38. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV (2000) Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 176, 53-59.
39. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH, Systolic Hypertension in Europe I (2002) The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162, 2046-2052.
40. Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F, Mullan MJ (2011) Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the bloodbrain barrier. Mol Med 17, 149-162.
41. Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, Mullan M (2004) Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 999, 53-61.
42. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS (2000) PSD-95 involvement in maturation of excitatory synapses. Science 290, 1364-1368.
43. Ueda T, Stratford CA, Larson J (1981) Distribution of protein I, a synapse-specific phosphoprotein, and adenylate cyclase in the rat spinal cord. J Neurochem 36, 293-296.
44. Chakroborty S, Goussakov I, Miller MB, Stutzmann GE (2009) Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci 29, 9458-9470.
45. Popugaeva E, Bezprozvanny I (2014) Can the calcium hypothesis explain synaptic loss in Alzheimer's disease Neurodegener Dis 13, 139-141.
46. Kamat PK, Kalani A, Givvimani S, Sathnur PB, Tyagi SC, Tyagi N (2013) Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice. Neuroscience 252C, 302-319.
47. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K (2013) Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis 33(Suppl 1), S123-S139.
48. Gantier R, Gilbert D, Dumanchin C, Campion D, Davoust D, Toma F, Frebourg T (2000) The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta. Neurosci Lett 283, 217-220.
49. Michel G, Mercken M, Murayama M, Noguchi K, Ishiguro K, Imahori K, Takashima A (1998) Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells. Biochim Biophys Acta 1380, 177-182.